Company Research Report: SUBLIMED
Company Overview
- Name: SUBLIMED
- Mission: For patients in pain, with caregivers
- Founded: No information is available
- Key People: No information is available
- Headquarters: 137, rue Mayoussard, 38430 Moirans, France
- Number of Employees: No information is available
- Revenue: No information is available
- Known For: Regulatory approved medical devices, specifically the actiTENS system, which is a medical neurostimulator for chronic pain relief.
Products
actiTENS
- Description: actiTENS is a regulatory-approved transcutaneous electrical nerve stimulation (TENS) neurostimulator designed to relieve chronic pain.
- Key Features:
- Carries CE marking (2797) indicating compliance with health, safety, and environmental protection standards.
- Considered superior to weak opioids such as Tramadol for managing knee osteoarthritis pain.
- App-based, enhancing accessibility and user management of the device.
- Better tolerated by patients in comparison to weak opioid treatments.
Recent Developments
- Clinical Study:
- A peer-reviewed clinical study published in January 2022 in Therapeutic Advances in Musculoskeletal Disease highlighted the effectiveness of actiTENS over traditional opioid treatments for knee osteoarthritis, suggesting a significant superiority in reducing pain and improving quality of life.
- Exposure in Publications:
- Featured in the Arab Health Exhibition magazine, presenting actiTENS as an example of successful French Medtech innovation.
- Regulatory Status:
- Maintains an ISO 13485 certification.
- Complies with EU Medical Device Regulation 2017/745 for assembly and manufacturing processes.
- Partnerships and Collaborations: No information is available
This report focuses solely on the available data about SUBLIMED, emphasizing its actiTENS product line. Further information regarding other aspects of the company's operations or product portfolio was not available in the provided data set.
